Ginsenoside Rk2
Catalog No: CFN92818
Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation
activities. Ginsenoside Rk1 can strongly inhibit permeability induced by VEGF, advance glycation end-product, thrombin, or histamine in human retinal endothelial cells, it reduces the vessel leakiness of retina in a diabetic mouse model; this anti-permeability activity of Rk1 is correlated with enhanced stability and positioning of tight junction proteins at the boundary between cells; Rk1 induces phosphorylation of myosin light chain and cortactin, which are critical regulators for the formation of the cortical actin ring structure and endothelial barrier.
Nothofagin
Catalog No: CFN92888
Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases. Nothofagin may have significant benefits in the treatment of diabetic complications. Nothofagin has potential to as an anti-sendothelial cell protein C receptor shedding reagent against phorbol-12-myristate 13-acetate and cecal ligation and puncture -mediated endothelial cell protein C receptor shedding.
